AI speeds up drug design for Parkinson’s ten-fold
The researchers, from the University of Cambridge, designed and used an AI-based strategy to identify compounds that block the clumping, or aggregation, of alpha-synuclein, the protein that characterises Parkinson’s.The team used machine learning techniques to quickly screen a chemical library containing millions of entries, and identified five highly potent compounds for further investigation. Parkinson’s affects more than six million people worldwide, with that number projected to triple by 2040. No…